Brooks Automation Reports Fourth Quarter Results of Fiscal Year Ended September 30, 2018

10 December 2018

CHELMSFORD, Mass., Nov. 19, 2018 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq: BRKS) today reported financial results for the fourth quarter and the fiscal year ended September 30, 2018.



GAAP Summary







Quarter Ended











Year Ended







Dollars in millions, except per share data



September 30, 



September 30, 











September 30, 



September 30, 











2018



2017



Change







2018



2017



Change



Revenue - Continuing Operations



$

160



$

135



19

%





$

632



$

527



20

%

Total Diluted EPS attributable to Brooks



$

0.15



$

0.25



(41)

%





$

1.64



$

0.89



85

%





 



Non-GAAP Summary

Aggregate View which includes the Semiconductor Cryogenics Business in each line







Quarter Ended











Year Ended







Dollars in millions, except per share data



September 30, 



September 30, 











September 30, 



September 30, 











2018



2017



Change







2018



2017



Change



Revenue - Continuing Operations



$

160



$

135



19

%





$

632



$

527



20

%

Revenue - Semiconductor Cryogenics



$

48



$

47



1

%





$

196



$

165



19

%

Aggregate view of Revenue



$

208



$

182



14

%





$

828



$

693



19

%









































Non-GAAP Total Diluted EPS

attributable to Brooks



$

0.40



$

0.35



15

%





$

1.57



$

1.23



27

%



The Company announced on August 27, 2018 it had entered into a definitive agreement to sell the Semiconductor Cryogenics business.  In accordance with GAAP, sales and expenses directly related to that business must be removed from their applicable income statement caption for continuing operations, and reported for all periods presented as net income from discontinued operations in the GAAP financial statements.  For this transition quarter, we present the non-GAAP summary above to provide a view of the entire business including the Semiconductor Cryogenics business aggregated line-by-line for a direct comparison to prior guidance and historical results. 

The Company provides additional non-GAAP information to provide investors a better perspective on the results of operations, which the Company believes is more comparable to the similar analysis provided by its peers.  A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets, statements of operations and statements of cash flows.

Management Comments

"Our 2018 fiscal year was strong from start to finish and has charted a new path with transformative M&A agreements that are reshaping the company," commented Steve Schwartz, CEO of Brooks Automation. "The acquisition of GENEWIZ, which we completed last week, is expanding our reach in sample services to thousands of additional customers, supported by a highly talented global team.  Further, we signed an agreement in August to sell our Semiconductor Cryogenics business and expect to complete the sale during our second fiscal quarter of 2019.  We believe these transactions strengthen our growth portfolio and extend our position as the leading provider of life science sample services.  Meanwhile we continued our strong operating performance in the semiconductor business and delivered yet another consecutive growth quarter in life sciences, yielding a 20% top-line growth for the year."

Commentary on GAAP Earnings for Fiscal Year 2018

Revenue excludes the Semiconductor Cryogenics revenue as a result of the pending sale of this business.  Profits related to this business are included in discontinued operations.

  • Total Earnings Per Share increased 85% for the fiscal year, driven by 20% revenue growth, gross margin expansion of 126 basis points, and a $43 million benefit of reversing a valuation allowance reserve on deferred tax assets. Fourth quarter net income declined 40% year over year, which reflects 19% growth in revenue and 16% growth at the gross profit line, offset largely by an increase in M&A costs, interest expense, and amortization of intangible assets driven by acquisitions.
  • Cash flow from operations for the fiscal year 2018 was $74 million, with $31 million in the fourth quarter. The cash balance expanded to $251 million at the end of the fourth quarter.
  • Subsequent to the fiscal year end, the Company closed on the acquisition of GENEWIZ, a global provider of gene sequencing and synthesis services. The transaction closed on November 15, 2018 for a cash price of approximately $450 million. The acquisition was funded from cash on the balance sheet and new debt in the form of an incremental $350 million term loan.

Commentary on Non-GAAP Earnings in an Aggregate View with Semiconductor Cryogenics Included

The aggregate view is shown on a non-GAAP basis for investors wishing to compare results to the performance reports provided in previous periods and to the Company's most recent guidance.

Fourth Quarter, Fiscal 2018

  • Non-GAAP EPS was $0.40 in the quarter, representing 15% growth year over year. The EPS growth were driven by 14% revenue growth and operating margin expansion through leverage of operating expense. The positive operating margin improvement was largely offset by interest expense on new debt in the year.
  • Life Sciences revenue was $51 million, 16% higher compared to Q4 2017, inclusive of 6% organic growth.
  • Semiconductor Solutions revenue was $157 million, a 14% improvement year over year and a decline of 10% compared to the third quarter of 2018.

Full Year, Fiscal Year 2018

  • 19% year over year revenue growth was driven by both business segments. Semiconductor Solutions, inclusive of the Cryogenics business, grew 19% for the year and was led by 25% year over year growth in automation product revenue. Life Sciences grew 32% for the year and was led by storage services growth of 31% year over year and the acquisition of 4titude. Life Science organic growth was 14% for the year.
  • Non-GAAP Diluted EPS for the fiscal year was $1.57, an improvement of 27% year over year. The EPS growth was driven by 19% revenue growth and gross margin expansion, compared to 2017. Increased interest expense was largely offset by lower tax rates year over year.

 



Non-GAAP Summary

Continuing Operations which excludes Semiconductor Cryogenics Business







Quarter Ended











Year Ended







Dollars in millions, except per share data



September 30, 



September 30, 











September 30, 



September 30, 











2018



2017



Change







2018



2017



Change



Revenue - Continuing Operations



$

160



$

135



19

%





$

632



$

527



20

%

Semiconductor Solutions Group





109





91



20

%







435





379



15

%

Life Sciences





51





44



16

%







197





149



32

%









































Non-GAAP Diluted EPS



$

0.17



$

0.12



36

%





$

0.64



$

0.44



44

%



Commentary on Non-GAAP Earnings for Continuing Operations with Semiconductor Cryogenics Excluded

The Continuing Operations view shown on a non-GAAP basis provides investors additional performance information by excluding the impact of M&A costs, amortization, restructuring, purchase price accounting, and special charges or gains.  This profile will be used in reporting future results. 

Fourth Quarter, Fiscal 2018

  • Non-GAAP EPS for the quarter was $0.17, an improvement of 36% year over year. Improved earnings was driven by the 20% year over year revenue growth and leverage of operating expense.
  • Revenue was $160 million in the fourth quarter. Sequentially, this was a decline of 7% compared to the third fiscal quarter of 2018. Semiconductor Solutions revenue declined 11% from the third quarter to $109 million. Life Sciences fourth quarter revenue grew 2% compared to the third fiscal quarter, the 13th quarter of sequential expansion.
  • Revenue in this view, which excludes the Semiconductor Cryogenics business, grew 19% year over year for the fourth quarter. Both business segments drove high year over year growth and Life Sciences has increased to be approximately 32% of fourth quarter revenue. With the addition of GENEWIZ, revenue from Life Sciences is expected to exceed 40% of total revenue.

  Full Year, Fiscal Year 2018

  • Non-GAAP EPS for the year increased 44% year over year to $0.64 per share. The growth in earnings was driven by 20% revenue growth and gross margin expansion.
  • Net interest expense for the year was $8 million, an increase of $8 million year over year. The company took on $200 million of debt in the first fiscal quarter of 2018 in anticipation of M&A activity through the year. This had an unfavorable impact on non-GAAP EPS of approximately $0.11 cents per share compared to 2017.
  • Taxes are applied to the specific jurisdictional mix of continuing versus discontinued operations. In doing so, the 2018 effective non-GAAP tax rate was approximately 16% for continuing operations and 2017 was approximately 25%.

A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures follows the consolidated balance sheets, statements of operations and statements of cash flows included in this release.

Quarterly Cash Dividend

The Company additionally announced that the Board of Directors has reiterated a dividend of $0.10 per share payable on December 20, 2018 to stockholders of record on December 7, 2018. Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company's Board of Directors.

Guidance for Fiscal First Quarter 2019

The Company announced revenue and earnings guidance for the first quarter of fiscal 2019.  Revenue from continuing operations is expected to be in the range of $170 million to $180 million and non-GAAP diluted earnings per share from continuing operations is expected to be in the range of $0.10 to $0.14.  Total GAAP diluted earnings per share, inclusive of the discontinued operations for the first quarter is expected to be in the range of $0.05 to $0.14.

Conference Call

Brooks management will webcast its fourth quarter earnings conference call today at 5:00 p.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.

The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Brooks' website at www.brooks.com, and will be archived online on this website for convenient on-demand replay. In addition, you may call 800-772-4206 (US & Canada only) or +1-212-271-4651 to listen to the live webcast.

About Brooks Automation, Inc.

Brooks is a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor manufacturing and life sciences. Brooks' technologies, engineering competencies and global service capabilities provide customers speed to market and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments.  Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market as a provider of precision automation and cryogenic vacuum solutions.  Since 2011, Brooks has applied its automation and cryogenics expertise to meet the sample storage needs of customers in the life sciences industry.  Brooks' life sciences offerings include a broad range of products and services for on-site infrastructure for sample management in temperatures of ‑20°C to -196°C, as well as comprehensive outsource service solutions across the complete life cycle of biological samples including collection, transportation, processing, storage, protection, retrieval and disposal.  Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, visit www.brooks.com.

"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include, but are not limited to statements about the expected timing for completion of our sale of the Semiconductor Cryogenics business, our revenue and earnings expectations, our ability to increase our profitability, our ability to improve or retain our market position, the expected financial results from our recently acquired GENEWIZ business and our ability to deliver financial success in the future. Factors that could cause results to differ from our expectations include the following:  the volatility of the industries the Company serves, particularly the semiconductor industry; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; the timing and effectiveness of cost reduction and cost control measures; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertakes no obligation to update the information contained in this press release.

CONTACTS:

Sherry Dinsmore

Brooks Automation

978.262.2400

sherry.dinsmore@brooks.com

John Mills

Partner

ICR, LLC

646.277.1254

john.mills@icrinc.com

BROOKS AUTOMATION, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(In thousands, except per share data)









Three Months Ended





Year Ended









September 30, 





September 30,









2018



2017





2018



2017



Revenue































Products





$

120,646



$

100,181





$

482,729



$

406,986



Services







39,000





34,391







148,831





120,513



Total revenue







159,646





134,572







631,560





527,499



Cost of revenue































Products







71,820





58,864







288,323





249,396



Services







25,206





21,741







97,156





79,216



Total cost of revenue







97,026





80,605







385,479





328,612



Gross profit







62,620





53,967







246,081





198,887



Operating expenses































Research and development







12,138





10,996







46,936





39,875



Selling, general and administrative







46,281





40,485







167,022





141,549



Restructuring charges







585





563







714





3,144



Total operating expenses







59,004





52,044







214,672





184,568



Operating income







3,616





1,923







31,409





14,319



Interest income







688





32







1,881





464



Interest expense







(2,679)





(122)







(9,520)





(408)



Gain on settlement of equity method investment





















1,847



Other expense, net







(257)





(30)







(3,304)





(1,702)



Income before income taxes and earnings of equity method investments







1,368





1,803







20,466





14,520



Income tax (benefit) provision







2,580





4,540







(47,251)





3,380



Income (loss) before equity in earnings of equity method investments





$

(1,212)



$

(2,737)





$

67,717



$

11,140



Equity in earnings of equity method investments





















(453)



Income (loss) from continuing operations







(1,212)





(2,737)







67,717





10,687



Income from discontinued operations, net of tax







11,563





20,123







48,747





51,925



Net income





$

10,351



$

17,386





$

116,464



$

62,612



Net loss attributable to noncontrolling interest

















111







Net income attributable to Brooks Automation, Inc.





$

10,351



$

17,386





$

116,575



$

62,612



Basic net income (loss) per share:































Basic net income (loss) per share from continuing operations





$

(0.02)



$

(0.04)





$

0.96



$

0.15



Basic net income per share from discontinued operations







0.16





0.29







0.69





0.75



Basic net income per share attributable to Brooks Automation, Inc.





$

0.15



$

0.25





$

1.65



$

0.90



Diluted net income (loss) per share:































Diluted net income (loss) per share from continuing operations





$

(0.02)



$

(0.04)





$

0.95



$

0.15



Diluted net income per share from discontinued operations







0.16





0.28







0.69





0.74



Diluted net income per share attributable to Brooks Automation, Inc.





$

0.15



$

0.25





$

1.64



$

0.89



































Dividend declared per share





$

0.10



$

0.10





$

0.40



$

0.40



































Weighted average shares outstanding used in computing net income per

share:































Basic







70,681





69,808







70,489





69,575



Diluted







71,085





70,681







70,937





70,485



































 

BROOKS AUTOMATION, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except share and per share data)





September 30, 



September 30,



2018



2017

Assets











Current assets











Cash and cash equivalents

$

197,708



$

101,622

Marketable securities



46,281





28

Accounts receivable, net



125,942





93,465

Inventories



96,986





73,397

Prepaid expenses and other current assets



31,741





22,594

Current assets held for sale



66,148





60,671

Total current assets



564,806





351,777

Property, plant and equipment, net



59,988





56,981

Long-term marketable securities



7,237





2,642

Long-term deferred tax assets



43,798





1,692

Goodwill



255,876





207,154

Intangible assets, net



99,956





83,504

Other assets



5,294





6,325

Non-current assets held for sale



59,052





56,553

Total assets

$

1,096,007



$

766,628

Liabilities and Stockholders' Equity











Current liabilities











Current portion of long term debt

$

2,000



$

Accounts payable



55,873





49,100

Deferred revenue



26,634





22,564

Accrued warranty and retrofit costs



6,340





5,479

Accrued compensation and benefits



29,322





23,876

Accrued restructuring costs



659





1,708

Accrued income taxes payable



6,746





11,417

Accrued expenses and other current liabilities



30,405





24,808

Current liabilities held for sale



7,388





7,825

Total current liabilities



165,367





146,777

Long-term debt



194,071





Long-term tax reserves



1,102





1,687

Long-term deferred tax liabilities



7,135





3,748

Long-term pension liabilities



4,255





1,783

Other long-term liabilities



5,547





4,336

Non-current liabilities held for sale



698





652

Total liabilities



378,175





158,983

Stockholders' Equity











Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding







Common stock, $0.01 par value - 125,000,000 shares authorized, 84,164,130 shares issued and

70,702,261 shares outstanding at September 30, 2018, 83,294,848 shares issued and 69,832,979

shares outstanding at  September 30, 2017



841





833

Additional paid-in capital



1,898,434





1,874,918

Accumulated other comprehensive income



13,587





15,213

Treasury stock at cost - 13,461,869 shares



(200,956)





(200,956)

Accumulated deficit



(994,074)





(1,082,363)

Total stockholders' equity



717,832





607,645

Total liabilities and stockholders' equity

$

1,096,007



$

766,628

 



BROOKS AUTOMATION, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)





Year Ended



September 30, 



2018



2017

Cash flows from operating activities











Net income

$

116,464



$

62,612

Adjustments to reconcile net income to net cash provided by operating activities:











Depreciation and amortization



37,429





28,149

Gain on settlement of equity method investment







(1,847)

Impairment of other assets







Stock-based compensation



19,822





17,278

Amortization of premium on marketable securities and deferred financing costs



710





252

Earnings of equity method investments



(6,788)





(9,381)

Loss recovery on insurance claim



(1,103)





Deferred income tax benefit



(45,217)





517

Pension settlement







(259)

Other gains on disposals of assets



(758)





(406)

Changes in operating assets and liabilities, net of acquisitions:











Accounts receivable



(29,213)





(11,178)

Inventories



(24,365)





(12,792)

Prepaid expenses and other current assets



(3,676)





(5,829)

Accounts payable



5,457





7,846

Deferred revenue



3,541





8,049

Accrued warranty and retrofit costs



(157)





1,602

Accrued compensation and tax withholdings



5,978





5,565

Accrued restructuring costs



(1,080)





(4,241)

Accrued pension costs







(32)

Accrued expenses and other current liabilities



(3,080)





10,319

Net cash provided by operating activities



73,964





96,224

Cash flows from investing activities











Purchases of property, plant and equipment



(12,787)





(12,677)

Purchases of technology intangibles







(240)

Purchases of marketable securities



(69,692)





Sales of marketable securities



1,584





3,590

Maturities of marketable securities



17,482





Acquisitions, net of cash acquired



(85,755)





(44,791)

Proceeds from (purchases of) other investments



500





(170)

Proceeds from sales of property, plant and equipment



200





100

Net cash used in investing activities



(148,468)





(54,188)

Cash flows from financing activities











Proceeds from issuance of common stock



2,826





2,040

Proceeds from term loan



197,554





Payment of deferred financing costs



(318)





(28)

Repayment of term loan



(1,500)





Common stock dividends paid



(28,285)





(27,932)

Net cash provided by (used in) financing activities



170,277





(25,920)

Effects of exchange rate changes on cash and cash equivalents



313





420

Net increase in cash and cash equivalents



96,086





16,536

Cash and cash equivalents, beginning of period



101,622





85,086

Cash and cash equivalents, end of period

$

197,708



$

101,622

Notes on Non-GAAP Financial Measures:

These financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusted the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, as well as other gains and charges that are not representative of the normal operations of the business. In this context, the Company has also removed the effect of reversing the valuation allowance reserve on the U.S. deferred income tax assets. Additionally, due to the pending sale of the Company's Semiconductor Cryogenics business, the results from this business are reported in discontinued operations in the current and prior periods.  As a result, the Company has chosen to show the Aggregate View of the business which includes the results of the Semiconductor Cryogenics business, which is considered a non-GAAP financial measure Management strongly encourages investors to review our financial statements and publicly-filed reports in their entirety and not rely on any single measure.

The following tables provide a reconciliation of Net income attributable to Brooks Automation, Inc. to our Non-GAAP adjusted net income attributable to Brooks Automation, Inc. on an aggregate view as well as a reconciliation from the aggregate view to Non-GAAP adjusted net on a continuing operations basis for the quarters ended September, 30, 2018, June 30, 2018 and September 30, 2017 and then fiscal years ended September 30, 2018 and 2017.





Quarter Ended





September 30, 2018



June 30, 2018



September 30, 2017









per diluted







per diluted







per diluted

Dollars in thousands, except per share data    



$



share



$



share



$



share

Net income attributable to Brooks Automation,

Inc.



$

10,351



$

0.15



$

22,717



$

0.32



$

17,386



$

0.25

Adjustments:





































Purchase accounting impact on inventory and

contracts acquired













736





0.01









Amortization of intangible assets





6,531





0.09





6,584





0.09





4,403





0.06

Restructuring charges





585





0.01





82





0.00





563





0.01

Merger costs





8,673





0.12





2,460





0.03





3,470





0.05

Adjustment of valuation allowance against deferred tax assets





690





0.01





690





0.01









Tax effect of adjustments





1,580





0.02





(800)





(0.01)





(1,300)





(0.02)

Net loss attributable to noncontrolling interest













(111)





(0.00)









Non-GAAP adjusted net income attributable

to Brooks Automation, Inc. - Aggregate view





28,410





0.40





32,358





0.46





24,522





0.35

Less: Income from discontinued operations, net of tax





(11,563)





(0.16)





(17,793)





(0.25)





(20,123)





(0.28)

Adjustments to discontinued operations:





































Amortization of intangible assets





(1)





(0.00)





(1)





(0.00)





(1)





(0.00)

Restructuring charges

























Merger costs





(4,364)





(0.06)





(2,082)





(0.03)









Tax effect of adjustments related to discontinued operations





(712)





(0.01)





2,348





0.03





4,239





0.06

Non-GAAP adjusted net income from discontinued operations





(16,640)





(0.23)





(17,528)





(0.25)





(15,885)





(0.22)

Non-GAAP adjusted net income attributable to continuing operations





11,770





0.17





14,830





0.21





8,637





0.12

   Stock based compensation, pre-tax





4,587





0.06





4,623





0.07





5,983





0.08

   Tax rate





9

%







10

%







13

%



Stock-based compensation, net of tax





4,188





0.06





4,022





0.06





5,205





0.07

Non-GAAP adjusted net income attributable to Brooks Automation, Inc.- excluding stock-based compensation



$

15,958



$

0.22



$

18,852



$

0.27



$

13,842



$

0.20







































Shares used in computing non-GAAP diluted net income attributable to Brooks Automation, Inc. per share









71,085









70,978









70,681

 





Year Ended





September 30, 2018



September 30, 2017









per diluted







per diluted

Dollars in thousands, except per share data    



$



share



$



share

Net income attributable to Brooks Automation, Inc.



$

116,575



$

1.64



$

62,612



$

0.89

Adjustments:

























Purchase accounting impact on inventory and contracts

acquired





1,896





0.03





523





0.01

Amortization of intangible assets





24,219





0.34





17,146





0.24

Restructuring charges





716





0.01





3,226





0.05

Merger costs





14,412





0.20





8,309





0.12

Less: Fair value adjustment of equity investment













(1,847)





(0.03)

Add: True-up of BioCision stub period adjustment













203





Adjustment of valuation allowance against deferred tax assets





(43,062)





(0.61)









Tax effect of adjustments





(2,438)





(0.03)





(3,157)





(0.04)

Tax Reform - rate change applied to deferred tax liabilities





(671)





(0.01)









Net loss attributable to noncontrolling interest





(111)





(0.00)









Non-GAAP adjusted net income attributable to Brooks Automation, Inc. - Aggregate view





111,536





1.57





87,015





1.23

Less: Income from discontinued operations, net of tax





(48,747)





(0.69)





(51,925)





(0.73)

Adjustments to discontinued operations:

























Amortization of intangible assets





(3)





(0.00)





(3)





(0.00)

Restructuring charges





(2)





(0.00)





(82)





(0.00)

Merger costs





(7,467)





(0.11)









Tax effect of adjustments related to discontinued operations





(10,043)





(0.14)





(3,855)





(0.05)

Non-GAAP adjusted net income from discontinued operations





(66,262)





(0.93)





(55,865)





(0.79)

Tax adjustments due to discontinued operations:

























Non-GAAP adjusted net income attributable to continuing operations





45,274





0.64





31,150





0.44

Stock-based compensation, pre-tax





18,856





0.27





16,638





0.24

Tax rate





11

%







15

%



Stock-based compensation, net of tax





16,838



$

0.24





14,142





0.20

Non-GAAP adjusted net income attributable to Brooks Automation, Inc.- excluding stock-based compensation



$

62,112



$

0.88



$

45,292



$

0.64



























Shares used in computing non-GAAP diluted net income attributable to Brooks Automation, Inc. per share









70,937









70,681

The following tables shows a reconciliation of revenue from the Semiconductor Solutions Group on a continuing operations basis to the revenue from the Semiconductor Solutions Group on an aggregate view which includes the Semiconductor Cryogenics Business for the quarters ended September 30, 2018, June 30, 2018 and September 30, 2017 and then fiscal years ended September 30, 2018 and 2017.



Quarter Ended







Year Ended



September 30, 



June 30, 



September 30, 







September 30, 



September 30, 

Dollars in thousands

2018



2018



2017







2018



2017

Revenue - Semiconductor Solutions Group

Continuing operations

$

108,789



$

122,660



$

90,626







$

435,019



$

378,790

Adjustments:

































Revenue - Cryogenics Business



47,941





51,117





47,307









196,095





165,386

Revenue - Semiconductor Solutions Group

Aggregate view

$

156,730



$

173,777



$

137,933







$

631,114



$

544,176

 

Cision View original content:http://www.prnewswire.com/news-releases/brooks-automation-reports-fourth-quarter-results-of-fiscal-year-ended-september-30-2018-300753211.html

SOURCE Brooks Automation